Evidence map›Paper›PMID 25776920›Full record

ArticleVaccine2015

Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.

Rebecca A Gladstone, Johanna M Jefferies, Anna S Tocheva, Kate R Beard, David Garley, Wei Wei Chong, Stephen D Bentley, Saul N Faust, Stuart C Clarke

Abstract read
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Population genetics of group BFrontiers in microbiology · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rebecca A GladstoneFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK.
Johanna M JefferiesFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, UK.
Anna S TochevaFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK.
Kate R BeardFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK.
David GarleyFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK.
Wei Wei ChongFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK.
Stephen D BentleyPathogen Genomics, Wellcome Trust Sanger Institute, UK.
Saul N FaustFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, UK; NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton Foundation NHS Trust, Southampton, UK.
Stuart C ClarkeFaculty of Medicine and Institute for Life Sciences, University of Southampton, UK; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, UK. Electronic address: s.c.clarke@soton.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The seven-valent pneumococcal conjugate vaccine (PCV7) was added to the UK national immunisation programme in September 2006. PCV13 replaced PCV7 in April 2010. As carriage precedes disease cases this study collected carried pneumococci from children each winter from 2006/7 to 2010/11 over PCV introduction. Conventional microbiology and whole genome sequencing were utilised to characterise pneumococcal strains. Overall prevalence of pneumococcal carriage remained stable. Vaccine serotypes (VT) decreased (p<0.0001) with concomitant increases in non-vaccine serotypes (NVT). In winter 2010/11 only one isolate of PCV7 VT was observed (6B). PCV13 unique VTs decreased between winters immediately preceding and following PCV13 introduction (p=0.04). Significant decreases for VTs 6B, 19F, 23F (PCV7) and 6A (PCV13) and increases for NVT 21, 23B, 33F and 35F were detected. The serotype replacement was accompanied by parallel changes in genotype prevalence for associated sequence types with clonal expansion contributing to replacement. By winter 2010/11, serotype coverage of PCV7 and PCV13 was 1% and 11% respectively. VT replacement was observed for PCV7 and PCV13 serotypes. Conjugate vaccine design and use requires continuous monitoring and revision.

Indexed as

Carrier StateChild, PreschoolFemaleGenome, BacterialGenotypeHeptavalent Pneumococcal Conjugate VaccineHigh-Throughput Nucleotide SequencingHumansInfantMaleNasopharynxPneumococcal InfectionsPneumococcal VaccinesSeasonsSequence Analysis, DNASerogroup13-valent pneumococcal vaccineHeptavalent Pneumococcal Conjugate VaccinePneumococcal VaccinesVaccines, ConjugateNext generation sequencingPneumococcal vaccinesSerotype replacementStreptococcus pneumoniaeWhole genome

Identifiers

PMID25776920
PMCPMC4392391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.